|
Headlines
Market news and breaking stories live from Dow Jones Newswires
Market Commentary
A technical analysis commentary of the major markets, only from INO
Smart Scan
A premium service, alerting you to changes in the market by web and email.
Extreme Futures / Stocks
Extreme Markets from all exchanges, updated throughout the trading day.
|
| |
|
Trade Triangle Technology, Advanced Charts, SmartScan, Trading Workshops.
The premier online video learning platform for traders.
Daily Portfolio Scan and Analysis
|
| |
|
Human Genome Sciences seeks approval for Zalbin76 days ago
(AP:NEW YORK) Human Genome Sciences Inc. said Wednesday it has filed for marketing approval of its hepatitis C drug Zalbin.
The Rockville, Md., company did not say when it expected a response to its biologics license application, which was submitted to the Food and Drug Administration. Human Genome Sciences said its partner Novartis AG will file for European Union approval before the end of 2009.
In the U.S., the companies will share marketing costs and profits. In the rest of the world, Novartis wants to market the drug under the name Joulferon. Novartis could pay Human Genome Sciences as much as $300 million if the drug is approved and reaches sales targets. Human Genome Sciences has received $207.5 million from the collaboration so far.
In morning trading, Human Genome Sciences stock slipped 25 cents to $27.67.
Copyright 2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
< Back to News Index
|
